cilostazol has been researched along with eicosapentaenoic acid in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 2 (50.00) | 24.3611 |
| 2020's | 1 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aiura, K; Kitajima, M; Suzuki, K; Ueda, M | 1 |
| Ito, Y; Kono, K; Miyazaki, Y; Nagata, S; Okada, Y; Yasaka, M; Yasumori, K | 1 |
| Fukuda, S; Kayano, R; Matsuo, T; Morofuji, Y; Nakagawa, S; Niwa, M; Ozawa, H; Watanabe, D | 1 |
| Abosheasha, MA; El-Gowily, AH | 1 |
4 other study(ies) available for cilostazol and eicosapentaenoic acid
| Article | Year |
|---|---|
The influence of platelets on the promotion of invasion by tumor cells and inhibition by antiplatelet agents.
Topics: Adenocarcinoma; Adenosine Diphosphate; Adult; Blood Platelets; Cell Line, Tumor; Cilostazol; Collagen; Drug Combinations; Drug Screening Assays, Antitumor; Eicosapentaenoic Acid; Epoprostenol; Hirudins; Humans; Laminin; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Neoplasm Proteins; Pancreatic Neoplasms; Platelet Activation; Platelet Aggregation Inhibitors; Proteoglycans; Tetrazoles; Thrombin | 2004 |
[Combination of percutaneous balloon angioplasty and aggressive medical intervention improves symptomatic basilar artery stenosis with a tortuous access route: case report].
Topics: Aged; Angioplasty, Balloon; Cerebral Angiography; Cerebral Infarction; Cilostazol; Eicosapentaenoic Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Tetrazoles; Vasodilator Agents; Vertebrobasilar Insufficiency | 2010 |
In vitro analysis of drugs that improve hyperglycemia-induced blood-brain barrier dysfunction.
Topics: Animals; Benzimidazoles; Biphenyl Compounds; Blood-Brain Barrier; Cilostazol; Disease Models, Animal; Eicosapentaenoic Acid; Electric Impedance; Hyperglycemia; Propranolol; Quinolines; Rats; Rats, Wistar; Reactive Oxygen Species; Tetrazoles | 2018 |
Superiority of cilostazol among antiplatelet FDA-approved drugs against COVID 19 M
Topics: Cilostazol; Coronavirus 3C Proteases; COVID-19 Drug Treatment; Drug Approval; Drug Evaluation, Preclinical; Drug Repositioning; Eicosapentaenoic Acid; Epoprostenol; Humans; Iloprost; Molecular Docking Simulation; Platelet Aggregation Inhibitors; Prasugrel Hydrochloride; SARS-CoV-2; Spike Glycoprotein, Coronavirus; United States; United States Food and Drug Administration | 2021 |